Kevin Gordon, Progyny Director, Sells $321,358 in Company Stock

Kevin Gordon, Progyny Director, Sells $321,358 in Company Stock

THE MONEYWISE JOURNAL  ·  finance  ·  Tuesday, September 15, 2026
Kevin Gordon, Progyny Director, Sells $321,358 in Company Stock

The transaction was disclosed in a regulatory filing, marking a notable insider trade.

By MoneyWise Guide

Kevin Gordon, a director of Progyny, recently sold $321,358 worth of the fertility‑benefits company’s shares. The transaction was disclosed in a regulatory filing, marking a notable insider trade.

Key Takeaways

  • Kevin Gordon, a Progyny director, sold $321,358 in company stock.
  • The sale was reported in a Form 4 filing with the U.S. Securities and Exchange Commission.
  • Insider transactions are required to be disclosed within two business days of the trade.
Metric Value Why it matters
Person Kevin Gordon Identifies the insider involved.
Position Director at Progyny Shows the level of corporate influence.
Transaction Amount $321,358 Size of the insider trade.

Who Is Kevin Gordon?

Kevin Gordon serves on the board of directors for Progyny, a company that provides fertility‑benefits solutions to employers and employees. As a director, Gordon participates in strategic decision‑making and governance, and he is subject to the same disclosure requirements as other corporate insiders.

What Is Progyny?

Progyny operates in the healthcare benefits sector, focusing on fertility and reproductive services. The company offers a platform that integrates medical coverage, financial assistance, and support resources for individuals seeking assisted reproductive technology. Its business model centers on partnerships with employers to deliver comprehensive fertility benefits to their workforce.

Details of the Stock Sale

The sale involved a total of $321,358 in Progyny shares. The transaction was reported in a Form 4 filing, which is the standard document used by insiders to disclose trades in their company’s securities. The filing indicates that the sale was executed within the regulatory window required by the Securities and Exchange Commission (SEC).

Regulatory Context

Under U.S. securities law, corporate insiders—including directors—must file Form 4 with the SEC within two business days of any purchase or sale of company stock. This requirement ensures that the market has timely access to information about insider activity, which can influence investor perception and market dynamics. The filing also includes details such as the number of shares traded, the price per share, and the transaction date, though those specifics are not provided in the source.

Implications for Investors

Insider trades can signal confidence or concern about a company’s prospects. A sale by a director may raise questions about the insider’s view of the company’s future, but it can also be part of routine portfolio management. Investors should consider the broader context, including the company’s financial performance, industry trends, and any other recent insider activity, before drawing conclusions.

Why It Matters

For shareholders, insider transactions are a key data point that can affect stock valuation and market sentiment. A director’s sale of over $300,000 in shares is significant enough to warrant attention, as it may reflect personal liquidity needs, portfolio rebalancing, or a change in outlook. Understanding the nature of such trades helps investors assess potential risks and opportunities in their holdings.

Frequently Asked Questions

What is a Form 4 filing?

A Form 4 is a mandatory disclosure submitted to the SEC by insiders—such as directors, officers, and large shareholders—within two business days of any trade in the company’s securities. It provides the public with details about the transaction.

Why do directors sell company stock?

Insiders may sell shares for various reasons, including personal liquidity needs, portfolio diversification, or tax planning. The sale itself does not necessarily indicate a negative view of the company.

How can I find more information about this transaction?

Public filings are available on the SEC’s EDGAR database. By searching for the company’s ticker symbol and the insider’s name, one can locate the Form 4 and review the transaction details.

Does this sale affect Progyny’s stock price?

Insider trades can influence market perception, but a single transaction’s impact on price depends on many factors, including overall market conditions and the company’s performance.

What should investors do after an insider sale?

Investors should review the company’s recent financial statements, earnings releases, and any other insider activity to form a comprehensive view before making investment decisions.

Bottom Line

Kevin Gordon’s sale of $321,358 in Progyny shares is a routine insider transaction that has been duly disclosed. While the trade may prompt closer scrutiny, it is one piece of a larger puzzle that investors should evaluate in the context of the company’s overall performance and market environment.

This is educational information, not personalized financial advice.

Reporting based on: original source.